Total Contribution Cash. In-kind** $ $ $ *Cash funding consist of … (list types of contributions). (NOTE: If Government Internal Research and Development (IR&D) expenses are included as contributions, then other documentation is required regarding the treatment of these expenses, i.e. whether Government funds are credited to an IR&D cost pool.) **In-kind contributions consist of … (list types of contributions but also include the basis for determining the in-kind value).
Total Contribution Cash. In-kind** Phase 1 $335,834 $335,834 $0 Phase 2 $583,461 $583,461 $0 Total $919,295 $919,295 $0 *Cash contributions consist of: Direct labor, to include indirect costs thereof, and direct materials/equipment purchases, to include indirect costs thereof, as included in Amyrsis’s Living Foundries proposal dated 3 May 2012 (as amended). The aforementioned are considered cash contributions made by Xxxxxx in support of the Living Foundries research program. **In-kind contributions consist of: N/A Modification P00013 Conformed Copy Enclosure 1 Agreement No. HR0011-12-3-0006 Attachment 5 List of Intellectual Property Assertions Technical Data Computer Software to be Furnished with Restrictions Basis for Assertion Asserted Rights Category Name of Person Asserting Restrictions Production of Isoprenoids, Application US 11/754,235, Patent No. US 7,659,097 (US 20080274523) Developed exclusively at private expense Restricted Rights Amyris, Inc. Production of Isoprenoids, ApplicationUS 12/638,771, Patent No. (US2011/0287476) Developed exclusively at private expense Restricted Rights Amyris, Inc. Production of Isoprenoids, Application PCT/US2007/069807, Patent No. (WO2007/140339) Developed exclusively at private expense Restricted Rights Amyris, Inc. Nucleic Acids, Compositions and Methods for the Excision of Target Nucleic Acids, Application US 12/978,061, Patent No. US 7,919,605 Developed exclusively at private expense Restricted Rights Amyris, Inc. Nucleic Acids, Compositions and Methods for the Excision of Target Nucleic Acids, Application US 13/220,553, Patent No. (US 2012/0052582) Developed exclusively at private expense Restricted Rights Amyris, Inc. Nucleic Acids, Compositions and Methods for the Excision of Target Nucleic Acids, Application PCT/US2011/049615, Patent No. (WO 2012/030747) Developed exclusively at private expense Restricted Rights Amyris, Inc. Compositions and Methods for the Rapid Assembly of Polynucleotides, Developed exclusively at private expense Application US 12/622,401, Patent No. (US 2010/0136633) Developed exclusively at private expense Restricted Rights Amyris, Inc. Compositions and Methods for the Rapid Assembly of Polynucleotides, Application US 12/684,874, Patent No. US 8,110,360 (US 2010/0124768) Developed exclusively at private expense Restricted Rights Amyris, Inc. [*] Developed exclusively at private expense Restricted Rights Amyris, Inc. [*] Developed exclusively at private expense Restricted Rights Amyris, Inc. [*] Certain portion...
Total Contribution Cash. In-kind** $ $ $ *Cash funding consist of … (list types of contributions). (NOTE: If Government Internal Research and Development (IR&D) expenses are included as contributions, then other documentation is required regarding the treatment of these expenses, i.e. whether Government funds are credited to an IR&D cost pool.) **In-kind contributions consist of … (list types of contributions but also include the basis for determining the in-kind value). ATTACHMENT 5: PROPERTY/EQUIPMENT Below is a list of equipment proposed to be purchased by the Performer with an acquisition value of greater than $5,000. The Government will the Disposition of Property to all equipment purchased under this Agreement in accordance with the terms and conditions of Article XI. Item Description Unit Price Quantity Total Projected Cost $ $ $ $ $ $
